Researchers have developed a novel peptide with a prolonged half-life that has demonstrated success in rhesus monkeys and mice for inhibiting HIV infections.
List view / Grid view
Filter the results
HIV is a disease still common in sub-Saharan Africa despite global research since 1982. This article delves into the trends, opportunities and key players in HIV research, exploring future possibilities for treating the disease.
A new discovery could lead to the development of a drug for untreatable strains of TB, which can target uptake of the very amino acid that enables the bacteria to spread within the body.
Isolated components found in the Saussurea controversa plant have antimicrobial and regenerative properties which could lead to a treatment for bone diseases.
Produced by Group A Streptococcus, researchers have discovered the S protein, which binds to the red blood cell membrane to avoid being destroyed by immune cells and could be a target for anti-virulence drugs.
Researchers have identified the protein Annexin A6 as a potential therapeutical target against diseases that are caused by the accumulation of cholesterol and other lipids in endosomes.
The ICR has revealed that during drug discovery, researchers should not use general search engines and vendor catalogue information to decide on their use of chemical probes.
A novel approach to better understand a basic defence mechanism of the immune system has been developed using the ISG15 protein which could lead to novel antimicrobial drugs.
Researchers have found that PGE2, a signalling molecule involved in inflammation, promotes colorectal cancer progression through a microRNA and targeting that microRNA could have therapeutic potential.
Researchers have found that soft tissue sarcoma cells stop a key metabolic process which allows them to spread and restarting that process could leave these cancers vulnerable treatments.
Scientists have developed a new method that accelerates the design and engineering of potential medicines and vaccines using glycosylation.
In a pre-clinical model of multiple sclerosis, orally treating susceptible mice with a microRNA from the diseased gut has prevented the disease.
A new signalling pathway has been identified that may help further the understanding of blood clot formation in cancer patients and presents a new drug target for reducing cancer-associated complications.